Physiological Responses to Laparoscopic Sleeve Gastrectomy: Focusing on Ghrelin

Hvidovre University Hospital

Status: Completed

Conditions: Bariatric Surgery

Treatments: Other: Placebo; Other: Ghrelin

Study type: Interventional

Funder types: Other

Identifiers

NCT04055025

H-19010763

Details and patient eligibility

About

Our hypothesis is that decreased concentration of ghrelin after LSG is important for the decreased appetite and food intake postoperatively. We therefore expect infusion of ghrelin will increase an ad libitum food intake after LSG. We also expect that a decreased postprandial concentration of ghrelin after LSG play a role for increased insulin secretion and decreased postprandial plasma glucose concentrations after surgery.

Full description

Laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy (LSG) are to bariatric procedure. After both procedures, a changed secretion of hormones from the gastrointestinal tract is believed to affect appetite and glucose metabolism. Studies have shown that after LRYGB, there is a significant increased secretion of GLP-1 and PYY. In contrast, a decreased secretion of ghrelin is a characteristic finding after LSG opposite post-LRYGB, where secretion of ghrelin is reported to be increased, decreased or unchanged. Ghrelin is primarily secreted from the gastric mucosa in the fasting state and decreases in response to food intake. Ghrelin stimulates food intake through appetite-regulating centers in the hypothalamus. Administration of exogenous ghrelin has been reported to stimulate appetite. In addition, ghrelin has recently been suggested also to affect glucose metabolism by inhibition of glucose-stimulated insulin secretion. Therefore the markedly decreased secretion of ghrelin could be of particular important for the decreased appetite and improved glucose tolerance seen after LSG.

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• The Danish national inclusion criteria for bariatric surgery
• Signed written informed consent
• Fasting plasma glucose <6.1 mmol/l

Exclusion criteria

• Pregnancy or breastfeeding.
• Hemoglobin <6.5 mM
• Newly emerged serious disease

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

Sleeve gastrectomy operated patients

Other group

Description:

Six test days in a randomized, patient-blinded, cross-over design

Treatment:

Other: Ghrelin

Other: Placebo